Historically, chemotherapy was the primary treatment for multiple myeloma, often associated with significant side effects and limited success. Over the past two decades, significant progress has been made, leading to more personalized and effective treatments. This evolution reflects a deeper understanding of the disease's biology and the integration of innovative therapies into existing protocols.

Today, treatment is increasingly tailored based on genetic and molecular profiling of the myeloma cells. This approach allows clinicians to select therapies that target specific pathways, optimizing efficacy and reducing toxicity. Precision medicine has transformed the prognosis for many patients diagnosed with this disease.

Combining traditional chemotherapy with targeted therapies such as proteasome inhibitors and immunomodulatory drugs has become standard. These combinations have demonstrated higher response rates and longer progression-free survival. Examples include regimens like VRd (bortezomib, lenalidomide, dexamethasone) plus chemotherapy agents for specific patient profiles.

Clinical trials continue to investigate promising options, including monoclonal antibodies, CAR-T cell therapies, and bispecific antibodies. These innovations aim to enhance the potency of chemotherapy regimens and overcome resistance, offering hope for more durable remissions.

With more potent therapies, managing side effects remains a priority. Supportive care strategies such as growth factor support, infection prevention, and symptom control are vital. Patient education and proactive management can significantly improve treatment adherence and quality of life.

The future holds the promise of even more personalized, targeted, and less toxic approaches. Advances in genomics and immunotherapy are paving the way for treatments that are not only more effective but also better tolerated, shifting the focus towards long-term disease control and improved survivorship.